BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26705180)

  • 1. [Expression of microRNA in ALK-negative anaplastic large cell lymphoma and CD30-positive peripheral T cell lymphoma, not otherwise specified].
    Wang C; Chen X; Chen X; He Y; Cao L
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):565-70. PubMed ID: 26705180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
    Ganapathi KA; Nicolae A; Egan C; Geng H; Xi L; Pack SD; McFadden JR; Raffeld M; Jaffe ES; Pittaluga S
    Br J Haematol; 2024 May; 204(5):1862-1871. PubMed ID: 38613165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.
    Bisig B; de Reyniès A; Bonnet C; Sujobert P; Rickman DS; Marafioti T; Delsol G; Lamant L; Gaulard P; de Leval L
    Haematologica; 2013 Aug; 98(8):1250-8. PubMed ID: 23716562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
    Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
    Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
    Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
    Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
    Geissinger E; Sadler P; Roth S; Grieb T; Puppe B; Müller N; Reimer P; Vetter-Kauczok CS; Wenzel J; Bonzheim I; Rüdiger T; Müller-Hermelink HK; Rosenwald A
    Haematologica; 2010 Oct; 95(10):1697-704. PubMed ID: 20511667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression profiling of microRNA and their target genes in peripheral T cell lymphoma, not otherwise specified].
    Li M; Lü N; Liu HX; Chen DB; Zhang JZ
    Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):519-24. PubMed ID: 24246916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
    Fitzpatrick MJ; Massoth LR; Marcus C; Vergilio JA; Severson E; Duncan D; Ramkissoon SH; Hasserjian RP; Kim AS; Sohani AR; Williams EA; Nardi V
    Am J Surg Pathol; 2021 Jul; 45(7):895-904. PubMed ID: 34105517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype.
    Ferreira CR; Zhao S; Sahoo MK; Pinsky B; Weber J; Lage LAPC; Pereira J; Zerbini MCN; Natkunam Y
    Hum Pathol; 2018 Oct; 80():138-144. PubMed ID: 29898383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
    Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
    Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
    Falini B; Bigerna B; Fizzotti M; Pulford K; Pileri SA; Delsol G; Carbone A; Paulli M; Magrini U; Menestrina F; Giardini R; Pilotti S; Mezzelani A; Ugolini B; Billi M; Pucciarini A; Pacini R; Pelicci PG; Flenghi L
    Am J Pathol; 1998 Sep; 153(3):875-86. PubMed ID: 9736036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.
    Laginestra MA; Piccaluga PP; Fuligni F; Rossi M; Agostinelli C; Righi S; Sapienza MR; Motta G; Gazzola A; Mannu C; Sabattini E; Bacci F; Tabanelli V; Sacchetti CA; Barrese TZ; Etebari M; Melle F; Clò A; Gibellini D; Tripodo C; Inghirami G; Croce CM; Pileri SA
    Blood Cancer J; 2014 Nov; 4(11):259. PubMed ID: 25382608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
    Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
    Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
    Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
    Li LL; Qu LL; Fu HJ; Zheng XF; Tang CH; Li XY; Chen J; Wang WX; Yang SX; Wang L; Zhao GH; Lv PP; Zhang M; Lei YY; Qin HF; Wang H; Gao HJ; Liu XQ
    Oncotarget; 2017 Jul; 8(28):45399-45414. PubMed ID: 28514730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre.
    McKelvie PA; Thompson PA; Tam CS
    Histopathology; 2012 Aug; 61(2):212-23. PubMed ID: 22716228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK-negative anaplastic large cell lymphoma with "Hodgkin-like" cytomorphology and nuclear expression of PAX5.
    Fratoni S; Niscola P; Zhao XF; Larocca LM; Capalbo A; Fabbretti M; Bernardini L; Abruzzese E
    Pathol Res Pract; 2020 Feb; 216(2):152724. PubMed ID: 31784094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.